Julien Alistair Brown

USPTO Granted Patents = 25 (Patent Applications = 1)

CIPO Patents = 10

EPO Patents = 13 (Patent Applications = 11)

Average Co-Inventor Count = 5.2

ph-index = 7

Forward Citations = 121(Granted Patents)

Location History:

Reading, GB (1999 - 2010)
Berkshire, GB (1999 - 2010)
Slough, GB (2012 - 2021)

Company Filing History:

Celltech Therapeutics Limited

where one patent can have more than one assignee

Years Active: 1999-2021

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10953019 - Fused pentacyclic imidazole derivatives as modulators of TNF activity (2021-03-23),

2. 10273247 - Imidazothiazole derivatives as modulators of TNF activity (2019-04-30),

3. 10087179 - Fused tricyclic imidazole derivatives as modulators of TNF activity (2018-10-02),

4. 10004737 - Fused imidazole and pyrazole derivatives as modulators of TNF activity (2018-06-26),

5. 9932342 - Imidazopyrimidine derivatives as modulators of TNF activity (2018-04-03),

6. 9890174 - Fused Tricyclic imidazole derivatives as modulators of TNF activity (2018-02-13),

7. 9873703 - Imidazopyridazine derivatives as modulators of TNF activity (2018-01-23),

8. 9714251 - Imidazotriazine derivatives as modulators of TNF activity (2017-07-25),

9. 9475820 - Substituted imidazo[1,2-a]pyrazines as TNF activity modulators (2016-10-25),

10. 9309243 - Imidazopyridine derivatives as modulators of TNF activity (2016-04-12),

11. 9029392 - Quinoline derivatives as kinase inhibitors (2015-05-12),

12. 8513284 - Fused pyridine and pyrazine derivatives as kinase inhibitors (2013-08-20),

13. 8324204 - Fused thiophene derivatives as kinase inhibitors (2012-12-04),

14. 8168634 - Thiazole derivatives as kinase inhibitors (2012-05-01),

15. 7786177 - Phenylalanine enamide derivatives (2010-08-31),

Title: Celebrating the Innovations of Julien Alistair Brown: A Pioneer in TNF Modulation

Introduction: Julien Alistair Brown, an accomplished inventor based in Slough, GB, has made significant contributions to the field of pharmaceuticals with a prolific portfolio of 25 patents. His work primarily focuses on developing new therapeutic agents aimed at modulating tumor necrosis factor (TNF) activity, a crucial component in treating various human ailments.

Latest Patents: Among his latest innovations are two noteworthy patents that showcase his expertise. The first patent involves "Fused pentacyclic imidazole derivatives as modulators of TNF activity." This series of substituted derivatives presents a promising approach to combatting autoimmune and inflammatory disorders, as well as neurological and neurodegenerative disorders, among others. The second patent titled "Imidazothiazole derivatives as modulators of TNF activity" highlights another class of compounds that potentially offer benefits in treating a wide array of illnesses, including metabolic, ocular, and oncological disorders.

Career Highlights: Julien has built a remarkable career, with substantial contributions while working at leading companies such as UCB Biopharma Sprl and UCB Pharma, S.A. His consistent focus on therapeutic innovation has paved the way for advancements in treatment methodologies targeting a variety of diseases.

Collaborations: Throughout his career, Julien has collaborated with esteemed colleagues, including John Robert Porter and Stephen Brand. These collaborations reflect a synergistic approach to research and development, enriching the innovation landscape within the pharmaceutical industry.

Conclusion: Julien Alistair Brown stands out as a trailblazer in the field of drug development. His 25 patents, particularly in TNF modulation, will undoubtedly continue to influence and drive forward the treatment options available for numerous health conditions, underlining his importance as a leading inventor in modern pharmacology.

This text is generated by artificial intelligence and may not be accurate.